Syndax Pharmaceuticals (SNDX) emphasized recurring revenue as a key driver of its financial trajectory during its presentation at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The biotech firm reported annualized revenue of over $200 million for its first approved drug, Revuforj (revumenib), six quarters into its launch, with Niktimvo (axatilimab), co-promoted with Incyte, annualizing around $240 million. Combined, the two drugs contributed roughly $440 million in annualized sales, marking an 84% revenue growth projection for fiscal 2026. While gross margins remain negative at approximately 8%, the company’s focus on repeat prescribing—particularly post-transplant maintenance therapy—has accelerated recurring revenue streams, now constituting the majority of revenue in any given period.
Revuforj, approved for KMT2A-rearranged acute leukemia and NPM1-mutated AML, has seen widespread adoption in combination therapies, with about 80% of patients receiving it alongside other treatments. Up to 70% of stem cell transplant patients are offered and receive Revuforj as post-transplant maintenance, a strategy that has driven durable remission rates. The MAINTAIN study, a randomized trial with Dana-Farber Cancer Institute, is evaluating revumenib’s role in eradicating minimal residual disease (MRD) post-transplant, with early data suggesting potential benefits in event-free survival.
Syndax’s pipeline remains robust, with four potential differentiated assets and two approved drugs expected by 2027. SNDX-4321, an allosteric EGFR inhibitor targeting osimertinib-resistant mutations in non-small cell lung cancer, is in IND-enabling studies, with clinical entry planned for 2027. SNDX-62122, a next-generation menin inhibitor for myelofibrosis, is also advancing, alongside a proof-of-principle study in myelofibrosis with the MPN Research Consortium.
Upcoming catalysts include Q4 readouts for two Phase III trials of axatilimab in idiopathic pulmonary fibrosis (MAXPIRe) and frontline cGVHD, as well as data from Dr. Brian Ball on post-transplant maintenance dosing. The company’s global IP for Revuforj extends through 2040, underscoring long-term protection for its lead asset.
Analysts noted the recurring revenue model as a critical differentiator, with Keith Goldhan, CFO, stating that the stacking effect from repeat prescriptions is already a major revenue driver. Nick Botwood, Chief Medical Officer, highlighted the clinical potential of allosteric inhibitors like SNDX-4321, which could address resistance mechanisms in EGFR-mutated lung cancer, potentially combining with osimertinib for enhanced efficacy.
Syndax’s growth strategy hinges on expanding its commercial footprint while advancing its pipeline, positioning the company as a leader in targeted cancer therapies with a focus on durable, repeatable outcomes.
